Abstract
The new, 2022, giant cell arteritis classification criteria1 from the American College of Rheumatology and European Alliance of Associations for Rheumatology (ACR–EULAR) represent substantial progress on the 1990 classification criteria and will underpin future scientific advancement in giant cell arteritis. Contrary to their stated use for classification of patients already diagnosed with primary systemic vasculitis, these criteria will inevitably (and unfortunately) be inappropriately used for diagnosis by some, even in the peer-reviewed literature,2 despite clear communication from the authors and sponsoring organisations about their intent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
